0       0


MN1-6: Navigating the Challenges of Monoclonal Antibodies and Transfusion Therapy


Oct 21, 2019 8:30am ‐ Oct 21, 2019 10:00am

Description

In the past decade, monoclonal antibody therapies targeting specific cellular receptors are having a major impact on treatment of malignancies of hematological origin and solid tumors. Monoclonal antibody therapies that target molecules that are also are present on red blood cells and platelets cause interference in routine blood bank pre-transfusion testing. These drugs include anti-CD38, approved for treatment of multiple myeloma but now used for a number of other malignancies and immune complications, anti-CD47 and CD47-related drugs in clinical trials for treatment of hematologic or solid malignancies, and alpha-4-inegrin antagonists among others. This session will focus not only on mitigation of test interference, but on the rational for use of these therapies and biological consequences.

Learning Objectives:

  • Review the development of immune therapy approaches and mechanisms of action.
  • Compare and contrast serologic reactivity seen when testing samples from patients receiving various monoclonal antibody therapies.
  • Discuss other potential targets that may be exploited in the future that are also present on RBCs and platelets.

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content